5 results
To evaluate the dose response relationship of LNP023 on the reduction in proteinuria versus placebo after 90 days of treatment in patients with IgA nephropathy.
The effect of correction of metabolic acidosis in chronic kidney disease on intrarenal RAS activity.
Primary Objective: - To study if sodiumbicarbonate therapy in patients with metabolic acidosis due to chronic kidney disease diminishes intrarenal RAS activity (without affecting the systemic RAS).Secondary Objective(s): - To study if…
Our objective is to investigate the value of a HVIGI in chronic midportion Achilles tendinopathy, using a dubbel-blind, placebo-controlled, randomised clinical trial. We expect that this study design gives us the opportunity to provide solid advise…
The purpose of this study is to ascertain the efficacy, safety, tolerability and pharmacokineticsof LNP023 over a 24-week treatment period compared with rituximab in subjects with MN.
The aim of this study is to determine whether LNP023 is effective and safe for the treatment of PNH. LNP023 is compared to the Standard of Care (SOC) anti-C5 antibody treatment. The primary objectives are to:• Demonstrate superiority of LNP023…